甲癬治療市場：依治療方法、類型和地區分類

Onychomycosis Treatment Market, By Treatment Type, By Type, By Geography

出版日期: 2026年03月30日 | 出版商:

Coherent Market Insights | 英文 162 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

據估計，2026年甲癬治療市場價值為37.55億美元，預計到2033年將達到54.97億美元。預計從2026年到2033年，該市場將以5.6%的複合年成長率成長。

分析範圍		分析詳情
基準年	2025	市場規模（2026 年）	37.55億美元
效能數據	2020-2024	預測期	2026-2033
預測期（2026-2033 年）複合年成長率	5.60%	預計金額（2033 年）	54.97億美元

甲癬是一種真菌感染疾病，會影響腳趾甲或手指甲，甚至可能影響指甲的任何組成部分。由於其療效顯著，治療仍是首選治療方法。新一代口服抗真菌藥物（Itraconazole和Terbinafine）正在取代傳統的甲癬治療方法。

市場動態

糖尿病患者患甲癬的風險增加、糖尿病盛行率上升、老年人口成長、對安全有效治療方法的需求增加、對開發新的甲癬治療方法的日益關注，以及公眾對甲癬潛在威脅和可用治療方法的認知提高，是預計在預測期內推動全球甲癬治療市場成長的主要因素。

例如，2021 年 4 月，Alembic Pharmaceuticals Limited（Alembic）宣布，其合資企業 Aleor Dermaceuticals Limited（Aleor）已獲得美國食品藥物管理局(FDA) 對其用於治療腳趾甲真菌的 efinaconazole腳指溶液的簡略新藥申請 (ANDA) 的臨時核准。

此外，2020年10月，Mundipharma在其BETADINE系列感染疾病治療產品中推出了一款新產品。這款BETADINE EMTRIX指甲抗黴菌溶液能有效治療甲癬，且長期使用可改善指甲外觀。

本報告的主要特點

本報告對全球甲癬治療市場進行了詳細分析，包括預測期（2026-2033 年）的市場規模和複合年成長率，以 2025 年為基準年。
此外，它還確定了每個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
本節根據以下參數，對全球甲癬治療市場的主要企業進行介紹：公司概況、產品系列、主要亮點、財務表現和策略。
本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、產品線更新、市場擴張和行銷策略做出明智的決策。
《全球甲癬治療市場》報告面向該行業的眾多相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過分析全球甲癬治療市場中使用的各種策略矩陣來促進決策。

北美洲
- 介紹
- 市場規模及預測、年成長率（YoY）：依治療方法分類
- 市場規模及預測、年增速（YoY）：依類別分類
美國
加拿大
歐洲
- 介紹
- 市場規模及預測、年成長率（YoY）：依治療方法分類
- 市場規模及預測、年增速（YoY）：依類別分類
英國
德國
法國
其他歐洲國家
亞太地區
- 介紹
- 市場規模及預測、年成長率（YoY）：依治療方法分類
- 市場規模及預測、年增速（YoY）：依類別分類
中國
日本
澳洲
印度
ASEAN
韓國
其他亞太地區
拉丁美洲
- 介紹
- 市場規模及預測、年成長率（YoY）：依治療方法分類
- 市場規模及預測、年增速（YoY）：依類別分類
墨西哥
巴西
其他拉丁美洲
中東
- 介紹
- 市場規模及預測、年成長率（YoY）：依治療方法分類
- 市場規模及預測、年增速（YoY）：依類別分類
波灣合作理事會（GCC）國家
非洲
- 介紹
- 市場規模及預測、年成長率（YoY）：依治療方法分類
- 市場規模及預測、年增速（YoY）：依類別分類
南非
其他中東和非洲地區

第7章競爭情勢

Lumenis Ltd.
Cipla Ltd.
Bayer AG
Johnson &Johnson
Moberg Pharma AB
Pfizer Inc.
Novartis
Galderma SA
Dr. Reddys Laboratories Ltd.
Medimetriks Pharmaceuticals Inc.
Bausch Health Companies Inc.（Valeant Pharmaceuticals Inc.）

第8章

分析方法
關於 Coherent Market Insights

簡介目錄

Product Code: CMI5423

Onychomycosis Treatment Market is estimated to be valued at USD 3,755 Mn in 2026 and is expected to reach USD 5,497 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.6% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 3,755 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	5.60%	2033 Value Projection:	USD 5,497 Mn

Onychomycosis is a fungal infection of the toenails or fingernails that may involve any component of the nail unit. For treatment, drugs remain the first-line treatment choice owing to a consistently high success rate. A newer generation of oral antifungal agents (itraconazole and terbinafine) has replaced older therapies in the treatment of onychomycosis.

Market Dynamics

Risk of onychomycosis in diabetic patient or increase in prevalence of diabetes, growing geriatric population, increase in demand for safe and effective treatment, rise in focus on the development of novel onychomycosis treatments, and growing awareness among people about potential threats of onychomycosis and available treatments are major factors expected to drive growth of the global onychomycosis treatment market over the forecast period.

For instance, in April 2021, Alembic Pharmaceuticals Limited (Alembic) announced that its joint venture Aleor Dermaceuticals Limited (Aleor) received tentative approval from the U.S. Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for Efinaconazole Topical Solution for the treatment of onychomycosis in the toenail.

Moreover, in October 2020, Mundipharma launched the latest addition to its BETADINE range of infectious disease therapies. This BETADINE EMTRIX fungal nail solutions effectively treats the onychomycosis and improves the nail appearance after regular application.

Key features of the study

This report provides in-depth analysis of the global onychomycosis treatment market, and provides market size (USD Mn) and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global onychomycosis treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Lumenis Ltd., Cipla Ltd., Bayer AG, Johnson & Johnson, Moberg Pharma AB, Pfizer Inc., Novartis, Galderma SA, Dr. Reddys Laboratories Ltd., Medimetriks Pharmaceuticals Inc., and Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.), among others.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global onychomycosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global onychomycosis treatment market.

Onychomycosis Treatment Market Segmentation

By Treatment Type Insights (Revenue, USD Mn, 2020 - 2033)
- Drugs
- Laser Therapy
- Photodynamic Therapy
By Type Insights (Revenue, USD Mn, 2020 - 2033)
- Distal Subungual Onychomycosis
- White Superficial Onychomycosis
- Proximal Subungual Onychomycosis
- Other Types
By Region Insights (Revenue, USD Mn, 2020 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
Key Players in the Onychomycosis Treatment Market
- Lumenis Ltd.
- Cipla Ltd.
- Bayer AG
- Johnson & Johnson
- Moberg Pharma AB
- Pfizer Inc.
- Novartis
- Galderma SA
- Reddys Laboratories Ltd.
- Medimetriks Pharmaceuticals Inc.
- Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.)
- Others.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Treatment Type
- Market Snapshot, By Type
- Market Snapshot, By Geography
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Increasing prevalence of onychomycosis around the world
- Availability of alternative treatment options
- Rise in demand for safe/effective onychomycosis treatment
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Onychomycosis Treatment Market, By Treatment Type, 2020-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2020 - 2033
- Segment Trends
Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
Laser Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
Photodynamic Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

5. Global Onychomycosis Treatment Market By Type, 2020-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2020 - 2033
- Segment Trends
Distal Subungual Onychomycosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
White Superficial Onychomycosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
Proximal Subungual Onychomycosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
Other Types
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)

6. Global Onychomycosis Treatment Market By Geography, 2020-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2020 - 2033
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2033, (USD Mn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2033, (USD Mn)
U.K.
Germany
France
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2033, (USD Mn)
China
Japan
Australia
India
ASEAN
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2033, (USD Mn)
Mexico
Brazil
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2033, (USD Mn)
GCC
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2033, (USD Mn)
South Africa
Rest of Middle East, and Africa

7. Competitive Landscape

Lumenis Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Cipla Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Moberg Pharma AB
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Galderma SA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Dr. Reddys Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Medimetriks Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bausch Health Companies Inc. (Valeant Pharmaceuticals Inc.)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Analyst Views